Background: Mucin 6 (also designated MUC 6 and gastric mucin) is a large glycoprotein that plays a major role in the protection of the gastrointestinal tract. MUC6 expression is highest in the stomach and gall bladder, with lower expression in the termi-nal ileum and right colon. In gastric cancer, MUC6 has an altered expression. In normal stomach, MUC6 apomucin is associated with Lewis type 2; MUC6 is also expressed in gastric metaplasia, duodenum and pancreas. MUC6 is a secretory mucin, located in the deeper mucosal folds of human gall bladder, and its expression is altered with increasing degrees of inflammation. MUC6 mRNA is expressed transiently in the nephrogenic zone of the kidney in the early mid-trimester of development, and MUC6 glycoprotein is expressed in the epithelium of ureteric buds and collecting ducts, but absent from adult kidney. Proliferating bile ductular cells express MUC6 apomucin in diseased liver, especially in chronic viral hepatitis with active necroinflammation, suggesting that this secreted mucin acts as a cytoprotective agent and represents a phenotype of reactive biliary epithelium in chronic viral hepatitis.
Description: Rabbit polyclonal to Muc6
Immunogen: KLH conjugated synthetic peptide derived from Muc6
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 252 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
